Permeability of the blood–brain barrier predicts no evidence of disease activity at 2 years after natalizumab or fingolimod treatment in relapsing–remitting multiple sclerosis
Annals of Neurology May 19, 2018
Cramer SP, et al. - Researchers ascertained if blood–brain barrier (BBB) permeability, as measured by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI), can provide early detection of suboptimal treatment response in relapsing–remitting multiple sclerosis (RRMS). For this investigation, 35 RRMS patients beginning on fingolimod or natalizumab, drugs with a common effect of decreasing lymphocyte influx into the central nervous system, were scanned with DCE-MRI at 3T prior to treatment and at 3 and 6 months posttreatment. They reported that BBB permeability as measured by DCE-MRI reliably predicts suboptimal treatment response and was a surrogate marker of the state of health of the BBB. A predictive threshold for disease activity was found, which was remarkably identical in clinically isolated syndrome and established RRMS as investigated here.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries